UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________ to ___________________________________________ Delaware 11-1719724 State or other jurisdiction of incorporation or organization (I.R.S. Emplo ...

EXHIBIT 99.1 United-Guardian Reports 2025 Financial Results HAUPPAUGE, N.Y., March 27, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2025 decreased compared to FY 2024. Net sales for the year decreased by 13% from $12,181,971 in 2024 to $10,545,468 in 2025, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,105,738 ($0.46 per share) in 2025. Donna Vigilante, President of United-Guardian, stated, "Our financial performance i ...

HAUPPAUGE, N.Y., March 27, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2025 decreased compared to FY 2024. Net sales for the year decreased by 13% from $12,181,971 in 2024 to $10,545,468 in 2025, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,105,738 ($0.46 per share) in 2025. Donna Vigilante, President of United-Guardian, stated, “Our financial performance in 2025 was primarily impacted by the decrease in sales of ou ...

Core Insights - The article highlights recent research reports on major stocks including Visa Inc., The Charles Schwab Corp., and Amphenol Corp., as well as micro-cap stocks Autoscope Technologies Corp. and United-Guardian, Inc. [2][4] Visa Inc. - Visa's shares have outperformed the Zacks Financial Transaction Services industry over the past year, with a gain of +11.1% compared to the industry's decline of -8.7% [4] - Total revenue rose 11% year-over-year in FY25, with cross-border growth at 13% [5] - The company faces rising client incentives and expenses, which may impact margin growth, with adjusted costs expected to rise nearly 11% in FY26 [6] The Charles Schwab Corp. - Charles Schwab's shares gained +21.8% over the past year, while the Zacks Financial - Investment Bank industry gained +37% [7] - The company is expected to maintain elevated expenses due to ongoing marketing investments, with a projected CAGR of 7% in expenses by 2027 [7][9] - Strategic buyouts and branch expansion efforts are anticipated to drive client assets, with total client assets expected to grow at a CAGR of 8.2% by 2027 [8][9] Amphenol Corp. - Amphenol's shares increased by +88.5% over the past year, slightly underperforming the Zacks Electronics - Connectors industry, which gained +89.8% [10] - The company benefits from a diversified business model and strong demand for high-speed and power interconnect products, with fourth-quarter 2025 earnings expected to grow between 62% and 65% year-over-year [12] - However, macroeconomic uncertainty and competition pose significant challenges [12] Autoscope Technologies Corp. - Autoscope Technologies has underperformed the Zacks Technology Services industry, with a decline of -5.5% compared to the industry's gain of +20.6% [13] - The company is focusing on AI-driven detection and multi-sensor integration, which supports future upgrades and broader use cases [13][14] - A new long-duration contract in Georgia enhances revenue visibility and diversifies its income sources [14][15] United-Guardian, Inc. - United-Guardian's shares have underperformed the Zacks Medical - Products industry, with a decline of -34.4% compared to -0.5% for the industry [16] - The company faces challenges such as declining profitability and operational strain, but it has strengths in expanding its pharmaceutical portfolio and stable medical products [17] - The upcoming launch of Natrajel is expected to provide a differentiated growth avenue [17]

Core Insights - The consumer staples sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1][2] Company Summaries - **SunOpta Inc (NASDAQ:STKL)**: Reported better-than-expected quarterly earnings with a 6.2% increase in stock price to close at $3.58. The stock has fallen approximately 35% over the past month, with an RSI value of 29.9 and a 52-week low of $3.32. The company has a momentum score of 91.92 and a value score of 93.51 [7] - **Energizer Holdings Inc (NYSE:ENR)**: Reported mixed fourth-quarter results and provided first-quarter EPS guidance below estimates. The stock rose 3.4% to close at $18.10, despite a 25% decline over the past month. The RSI value is 26, with a 52-week low of $17.13 [7] - **United-Guardian**: Experienced a decline in third-quarter earnings, with a 0.1% decrease in stock price to close at $5.68. The stock has fallen around 22% over the past month, with an RSI value of 21.4 and a 52-week low of $5.58. The company noted increased sales in pharmaceuticals and medical products but a decrease in cosmetic ingredient sales due to geopolitical issues [7]

Core Insights - The consumer staples sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1][2] Company Summaries - **SunOpta Inc (NASDAQ:STKL)**: Reported better-than-expected quarterly earnings with a 6.2% increase in stock price to $3.58. The stock has fallen approximately 35% over the past month, with an RSI value of 29.9 and a 52-week low of $3.32 [7] - **Energizer Holdings Inc (NYSE:ENR)**: Reported mixed fourth-quarter results and provided first-quarter EPS guidance below estimates. The stock rose 3.4% to close at $18.10, but has decreased around 25% in the last month, with an RSI value of 26 and a 52-week low of $17.13 [7] - **United-Guardian**: Experienced a decline in third-quarter earnings, with a 0.1% decrease in stock price to $5.68. The stock has fallen about 22% over the past month, with an RSI value of 21.4 and a 52-week low of $5.58 [7]

Core View - United-Guardian, Inc. has experienced a significant decline in both sales and net income for the third quarter of 2025, with net sales falling 26% year-over-year to $2.26 million and net income dropping to $268,441, reflecting a challenging market environment [2][4]. Financial Performance - For Q3 2025, net sales decreased by 26% to $2.26 million from $3.06 million in Q3 2024, while net income fell to $268,441 from $865,484, resulting in a 68% drop in earnings per share to 6 cents from 19 cents [2]. - For the first nine months of 2025, net sales declined 22% to $7.58 million from $9.71 million, and net income decreased to $1.46 million from $2.75 million, with earnings per share down about 47% to 32 cents from 60 cents [2]. Revenue Mix & Key Metrics - The decline in sales was primarily driven by weakness in the cosmetic ingredients business, while sales of pharmaceutical products and medical lubricants increased by 10% and 6%, respectively, over the first nine months of 2025 compared to the same period in 2024 [3]. Market Challenges - The softness in the cosmetic segment is attributed to reduced purchases by Ashland Specialty Ingredients (ASI), the company's largest marketing partner, which has faced tariff and geopolitical challenges in Asia, leading to a shift towards lower-priced local suppliers [4]. - ASI's efforts to manage excess inventory have resulted in decreased orders from United-Guardian, negatively impacting overall sales [4]. Operational Performance - Income from operations fell to $215,072 in Q3 2025 from $949,128 a year earlier, and for the nine months, it decreased to $1.52 million from $3.09 million in 2024 [5]. - Other income sources, including investment income and gains on marketable securities, also declined year-over-year, further dampening overall financial results [5]. Management Insights & Strategic Initiatives - Management remains optimistic about the underlying strength in pharmaceutical and medical businesses, with plans to regain market share through competitive pricing strategies [6]. - Key growth initiatives include focusing on Renacidin, with efforts to secure placement on additional drug formularies to significantly increase sales [7]. - The company has entered a strategic distribution arrangement to expand its sexual wellness and personal care portfolio, aiming to diversify revenue sources and broaden geographic reach [8]. Profitability Factors - Profitability was pressured by an increase in the cost of sales as a percentage of net sales, reflecting product-mix shifts and a challenging pricing environment, particularly in the cosmetic ingredients segment [9]. - Operating expenses rose due to higher professional fees and increased research and development spending, which, while supporting long-term growth, added to near-term earnings pressure [10][11]. Outlook - Although United-Guardian did not provide numerical guidance for the remainder of 2025, management expressed a cautiously optimistic outlook, relying on ASI's efforts to restore competitiveness and distribution expansions to stabilize cosmetic ingredient sales [13]. - The current earnings weakness is viewed as driven more by external demand and inventory dynamics rather than a decline in the company's product portfolio [14]. Shareholder Returns - The company has continued its practice of returning cash to shareholders through dividends, declaring and paying out cash dividends during the first nine months of 2025, including a 35 cents per share dividend earlier in the year [15].

Financial Performance - Net sales for the three months ended September 30, 2025, were $2,264,261, a decrease from $3,060,113 in the same period of 2024, representing a decline of approximately 26%[14] - The net income for the nine months ended September 30, 2025, was $1,456,162, down from $2,747,151 in the same period of 2024, reflecting a decrease of about 47%[14] - For the third quarter of 2025, total sales amounted to $2,264,261, a decrease from $3,060,113 in the same period of 2024, representing a decline of approximately 26%[54] - Cosmetic ingredient sales for the first nine months of 2025 were $1,998,948, down from $4,585,443 in 2024, reflecting a decrease of about 56%[54] - Pharmaceutical sales increased to $3,848,474 for the nine months ended September 30, 2025, compared to $3,485,994 in 2024, marking an increase of approximately 10%[54] - Sales to the United States for the nine months ended September 30, 2025, were $5,663,509, down from $8,089,868 in 2024, a decline of approximately 30%[56] Assets and Liabilities - The total current assets as of September 30, 2025, were $11,246,893, down from $12,665,551 as of December 31, 2024, a decrease of about 11%[16] - Total liabilities as of September 30, 2025, were $1,597,909, a decrease from $1,914,469 as of December 31, 2024, reflecting a reduction of about 17%[18] - The company’s total stockholders' equity as of September 30, 2025, was $10,582,436, down from $11,882,866 as of December 31, 2024, indicating a decline of about 11%[18] - Cash and cash equivalents at the end of the period were $860,836, a significant decrease from $1,875,655 at the beginning of the period, representing a decline of approximately 54%[16] - Total inventories as of September 30, 2025, were valued at $1,408,703, a decrease from $1,451,995 as of December 31, 2024[71] Operating Activities - The company reported a net cash provided by operating activities of $1,636,324 for the nine months ended September 30, 2025, compared to $3,196,954 in the same period of 2024, a decrease of approximately 49%[25] - Cash from operations decreased to $1,636,324 for the nine months ended September 30, 2025, down from $3,196,954 for the same period in 2024[127] - Cash provided by investing activities was $115,577 for the nine months ended September 30, 2025, compared to cash used of $6,241,837 for the same period in 2024[128] - Cash used in financing activities was $2,766,720 for the nine months ended September 30, 2025, compared to $2,756,323 for the same period in 2024[129] Research and Development - Research and development expenses for the three months ended September 30, 2025, were $117,104, compared to $111,072 in the same period of 2024, indicating an increase of approximately 5%[14] - Research and development expenses rose by $6,032 (5%) in Q3 2025 and by $13,652 (4%) for the first nine months of 2025 compared to the same periods in 2024[120] Market and Sales Trends - Approximately 31% of total sales in Q3 2025 were to customers outside the United States, up from 20% in Q3 2024[54] - For the nine months ended September 30, 2025, approximately 79% of ASI's sales were to foreign customers, with China accounting for about 39% of total sales, down from 45% in the same period of 2024[57] - The company is closely monitoring the impact of tariffs, particularly the 10% retaliatory tariff from China, which could significantly affect sales and gross margins[33][34] - The Company is closely monitoring its supply chain and pursuing growth initiatives to mitigate the impact of tariffs and global economic uncertainties[104] Investment and Securities - The net gains recognized during the three months ended September 30, 2025, on marketable securities amounted to $36,238, compared to $47,223 for the same period in 2024[64] - Total marketable securities as of September 30, 2025, had a fair value of $7,443,756, with unrealized gains of $103,648[67] - The company’s marketable equity securities are valued using Level 1 inputs, with fair value determined based on quoted prices in active markets[66] Taxation - The total provision for income taxes for the nine months ended September 30, 2025, was $368,874, compared to $720,494 for the same period in 2024[72] - The effective income tax rate was approximately 20% for the first nine months of 2025 and 2024, expected to remain the same for the current fiscal year[123] Miscellaneous - The company entered into a distribution agreement with Brenntag Specialties for the new Natrajel® line of sexual wellness ingredients, with manufacturing expected to begin in 2026 due to delays[27] - The new Medicare Part D Manufacturer Discount Program is expected to increase rebate liabilities for drug manufacturers, impacting financial results[48] - The allowance for credit losses related to accounts receivable was $14,092 as of September 30, 2025, slightly down from $14,342 at the end of 2024[44] - The allowance for credit losses is based on the Current Expected Credit Losses (CECL) model, reflecting ongoing credit evaluations and historical experience[58] - The company accrued $86,250 in contributions to the 401(k) defined contribution plan as of September 30, 2025, compared to $81,750 in 2024[75] - The company’s total accrued expenses as of September 30, 2025, were $1,341,540, down from $1,467,933 as of December 31, 2024[78]

Sales Performance - Sales for the nine-month period ended September 30, 2025, decreased to $7,583,613 from $9,705,262 in 2024, representing a decline of approximately 22.0%[2] - Third quarter sales fell to $2,264,261 in 2025 from $3,060,113 in 2024, a decrease of approximately 26.0%[2] - Sales of pharmaceutical products increased by 10% and medical products by 6% during the first nine months of 2025 compared to the same period in 2024[3] Net Income - Net income for the nine months ended September 30, 2025, decreased to $1,456,162 ($0.32 per share) from $2,747,151 ($0.60 per share), a decrease of about 47.1%[2] - Net income for the third quarter of 2025 was $268,441 ($0.06 per share), down from $865,484 ($0.19 per share) in the same quarter of 2024, a decline of about 69.0%[2] Cost Management - Total costs and expenses for the nine months ended September 30, 2025, were $6,062,166, down from $6,614,849 in 2024[8] - Research and development expenses for the nine months ended September 30, 2025, were $339,366, slightly up from $325,714 in 2024[8] Market Challenges and Opportunities - The decrease in cosmetic ingredient sales in the third quarter was primarily due to reduced purchases by Ashland Specialty Ingredients, attributed to tariff and geopolitical concerns in Asia[3] - United-Guardian is working with an outside pharmaceutical consultant to increase sales of Renacidin by including it in additional drug formularies, which is expected to significantly boost sales in the coming years[3] - New marketing agreements for personal care products have been negotiated, providing opportunities for revenue growth in the future[3]

Core Insights - United-Guardian, Inc. reported a decline in sales and net income for both the third quarter and the first nine months of 2025 compared to the same periods in 2024 [1][2]. Financial Performance - For the nine-month period ended September 30, 2025, sales decreased from $9,705,262 in 2024 to $7,583,613 in 2025, representing a decline of approximately 22% [1]. - Net income for the same period fell from $2,747,151 ($0.60 per share) in 2024 to $1,456,162 ($0.32 per share) in 2025, a decrease of about 47% [1]. - In the third quarter, sales dropped from $3,060,113 in 2024 to $2,264,261 in 2025, a decline of around 26% [1]. - Net income for the third quarter decreased from $865,484 ($0.19 per share) in 2024 to $268,441 ($0.06 per share) in 2025, a reduction of approximately 69% [1]. Segment Performance - Sales of pharmaceutical products increased by 10% and medical products by 6% during the first nine months of 2025 compared to the same period in 2024 [2]. - However, there was a decrease in sales of cosmetic ingredients in the third quarter of 2025, primarily due to reduced purchases by Ashland Specialty Ingredients (ASI), the company's largest marketing partner [2]. - ASI faced challenges related to tariffs and geopolitical issues in Asia, leading to a shift towards lower-cost local products by some customers [2]. Future Outlook - The company is optimistic about increasing sales of Renacidin, its most important pharmaceutical product, through new marketing strategies and partnerships [2]. - Recent marketing agreements for new personal care products are expected to provide opportunities for revenue growth in the coming years [2].